Japan's Alchemedicine & Asahi Kasei sign $270 mn license deal

Under the terms of the agreement, Asahi Kasei Pharma acquires exclusive global rights to research, develop, manufacture, and commercialize the Compounds. In return, Alchemedicine will receive an upfront payment and development, regulatory, and sales milestones totaling up to ¥41.3 billion, as well as royalties based on future product sales.

This agreement brings together Alchemedicine’s proprietary HiSAP medicinal chemistry platform with Asahi Kasei Pharma’s R&D expertise and international business foundation as it advances its evolution into a global specialty pharmaceutical company with a focus on autoimmune diseases. Through this partnership, the two companies aim to deliver new therapeutic options for intractable diseases and to foster sustainable growth for both organizations.

Under the agreement, Asahi Kasei Pharma will further evaluate potential therapeutic indications, which are expected to include autoimmune diseases based on the mechanism of the Compounds.

Both companies will continue working toward the creation of innovative medicines to address unmet medical needs in severe and refractory diseases.

Note: The headline, insights, and image of this press release may have been refined by the ALCHEMPro staff; the rest of the content remains unchanged.

ALCHEMPro News Desk (JP)